Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Design Therapeutics, Inc.DSGN-6.650.001.18-1.48-17.78%-12.89%32.98$5.41$12.792,506$5.61

Detail of Design Therapeutics, Inc.

 
CEO
Mr. Pratik Shah Ph.D.
Employees
54
Industry
Biotechnology
Sector
Healthcare
Market cap
$318M

Company details

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Design Therapeutics, Inc.
DSGN • XNGS • US
$5.61
+3.33 (146.05%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.84
Margin profit
0.00%
52 week low
$2.27
52 week high
$7.705
50-day simple moving average
$0.00
200-day simple moving average
$5.41
Percent held by insiders
36.45%
Percent held by institutions
56.88%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
DSGN +144.98%
eps change
DSGN 0.00%